Giant pituitary adenomas comprise about 6–10% of all pituitary tumors. They are mostly
clinically non-functioning adenomas and occur predominantly in males. The presenting …

A subset of pituitary neuroendocrine tumors (PitNETs) have an aggressive behavior,
showing resistance to treatment and/or multiple recurrences in spite of the optimal use of …

In aggressive pituitary tumors (PT) showing local invasion or growth/recurrence despite
multimodal conventional treatment, temozolomide (TMZ) is considered a further therapeutic …

Pituitary tumors (PT) represent in, the majority of cases, benign tumors for which surgical
treatment still remains, except for prolactin-secreting PT, the first-line therapeutic option …

ABSTRACT Pituitary adenomas comprise approximately 10-20% of intracranial tumors. Non-
functioning pituitary adenomas (NFPAs) are benign adenohypophyseal tumors not …

BACKGROUND AND PURPOSE: Due to its high sensitivity, somatostatin receptor–PET may
detect smaller lesions and more extensive disease than contrast-enhanced MR imaging …

Non-functioning pituitary adenomas (NFPAs) are benign pituitary tumours that constitute
about one-third of all pituitary adenomas. They typically present with symptoms of mass …

Nickel is used in many cerebral endovascular treatment devices. However, nickel
hypersensitivity is the most common metal allergy, and the relative risk of treatment in these …

Pituitary tumors are a heterogeneous group of lesions (usually benign) and proper
understanding of the anatomy, physiology, and pathology of the hypothalamic/pituitary …

Context Gonadotroph tumors represent approximatively one-third of anterior pituitary tumors,
but despite their frequency, no medical treatment is currently recommended for them. This …